Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 12/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 12/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.39 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.39 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492855 | 0.86 | ATM (0.45) | MKNK1MKNK2ATMCYP3A4FYN | |
| SCHEMBL3491072 | 0.70 | ALDH1A1 (0.60) | ATMFYN | |
| SCHEMBL14145116 | 0.69 | ATM (0.63) | MKNK1MKNK2ATMCYP3A4FYN | |
| SCHEMBL3490519 | 0.69 | FYN (0.55) | ATMFYN | |
| SCHEMBL25148814 | 0.69 | CHEK1 (0.46) | MKNK1MKNK2ATMCYP3A4FYN | |
| SCHEMBL25149703 | 0.69 | ATM (0.51) | MKNK1MKNK2ATMCYP3A4FYN | |
| SCHEMBL14145396 | 0.68 | ATM (0.62) | MKNK1MKNK2ATMCYP3A4FYN | |
| SCHEMBL3850100 | 0.67 | PIK3CA (0.53) | MKNK1MKNK2ATMCYP3A4FYN | |
| SCHEMBL30209308 | 0.66 | FYN (0.55) | MKNK1MKNK2ATMFYN | |
| SCHEMBL3490655 | 0.66 | PIK3CA (0.42) | MKNK1MKNK2CYP3A4EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | MKNK1 577/4885MKNK2 877/4885ATM 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.